Onabet Cream | Generic Ertaczo | Dosage | Uses | Side effects

Onabet Cream (Generic Ertaczo) - Active Ingredient And Chemical structure

The active ingredient contained in Onabet Cream is Sertaconazole Nitrate. Each gram of Onabet Cream, 2%, contains 17.5 mg of sertaconazole (as Sertaconazole Nitrate, 20 mg) in a white cream base. Benzyl Alcohol is used as the preservative. Sertaconazole Nitrate is a white or almost white powder. It is practically insoluble in water, soluble in methanol, sparingly soluble in alcohol and in methylene chloride. The structure is shown below

Generic Forms and Brand names of Ertaczo Cream

Onabet Cream manufactured by Glenmark Pharmaceuticals Ltd, India is an effective treatment for the topical treatment of fungal skin infections such as athlete's foot (tinea pedis) in immunocompetent patients 12 years of age and older. Ertaczo Cream which has the active ingredient Sertaconazole Nitrate is also sold under various other brand names.

Onabet Cream - Preparations

Onabet Cream 2% is available in a tube containing 15 grams of cream.

Onabet Cream - Storage Requirements

Onabet Cream is to be stored at room temperature (below 25°C). Store away from heat, moisture, and light. Do not freeze.

Onabet Cream (Generic Ertaczo) - Uses

Generic Ertaczo (Sertaconazole Nitrate Cream) in the form of Onabet Cream 2% is used for the topical treatment of fungal skin infections such as athlete's foot (tinea pedis) in immunocompetent patients 12 years of age and older, caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum. Sertaconazole Nitrate also has antibacterial action.

Onabet Cream (Generic Ertaczo) - Dosage

The recommended dosage of Generic Ertaczo Cream for various indications are:
Treatment of Superficial Fungal Infection of the Skin :
In the treatment of superficial fungal infection of the skin Onabet Cream 2%, should be applied twice daily for two weeks.
Treatment of Interdigital Tinea Pedis:
In the treatment of Interdigital Tinea Pedis, Onabet Cream 2%, should be applied twice daily for four weeks. Sufficient Generic Ertaczo Cream, 2%, should be applied to cover both the affected areas between the toes and the immediately surrounding healthy skin of patients with interdigital tinea pedis.

Side Effects Of Onabet Cream (Generic Ertaczo Cream)

The most common side effects of Onabet Cream included minor skin reactions such as contact dermatitis, erythema, pruritus, vesiculation, desquamation, hyperpigmentation, dry skin, burning skin, application site reaction and skin tenderness .

Further Information

Prescribing Information

Predmet Tablets | Generic Medrol | Dosage | Uses | Side effects

Predmet Tablets (Generic Medrol) - Active Ingredient And Chemical structure

The active ingredient contained in Predmet Tablets is Methylprednisolone which is a glucocorticoid. Methylprednisolone is a white, odourless, crystalline powder that is insoluble in water, sparingly soluble in alcohol, slightly soluble in acetone, and in chloroform, and very slightly soluble in ether. The structure is shown below

Generic Forms and Brand names of Medrol

Predmet Tablets manufactured by Sun Pharmaceutical Industries Ltd, India is an effective treatment for inflammatory effects in disorders of different parts of the body. Medrol which has the active ingredient Methylprednisolone Sodium Succinate is also sold as Solu-Medrol, Melpred and under various other brand names.

Predmet Tablets - Preparations

Predmet is available as tablets of 4 mg, 8 mg and 16 mg tablets. Each Medrol tablet contains 4 mg 8 mg or 16 mg of methylprednisolone.

Predmet Tablets - Storage Requirements

Predmet Tablets are to be stored at room temperature (15°C to 30°C). Store away from heat, moisture, and light.

Generic Medrol (Methylprednisolone Sodium Succinate) - Uses

Generic Medrol in the form of Predmet Tablets is primarily used to treat inflammatory conditions in various organ systems of the body. It is also used for varrious other indications as detailed below:

Endocrine Disorders: Primary or secondary adrenocortical insufficiency, Congenital adrenal hyperplasia. Nonsuppurative thyroiditis. Hypercalcemia associated with cancer.

Rheumatic Disorders: As adjunctive therapy for short-term administration in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis, ankylosing spondylitis;acute and subacute bursitis; acute non specific tenosynovitis; acute gouty arthritis; post-traumatic osteoarthritis; synovitis of osteoarthritis; epicondylitis.

Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus; systemic dermatomyositis (polymyositis); acute rheumatic carditis; polymyalgia rheumatica; giant cell arteritis.

Dermatologic Diseases: pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative dermatitis; mycosis fungoides; severe psoriasis; severe seborrheic dermatitis.

Allergic State: Control of severe of incapacitating allergic conditions intractable to adequate trials of conventional treatment.

Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa.

Respiratory Diseases: symptomatic sarcoidosis; Loeffler’s syndrome not manageable by other means; berylliosis; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; aspiration pneumonitis.

Hematologic Disorders: idiopathic thrombocytopenic purpura in adults; secondary thrombocytopenia in adults; acquired (autoimmune) hemolytic anemia; erythroblastopenia (RBC anemia); congenital (erythroid) hypoplastic anemia.

Neoplastic Disorders: For palliative management of: leukemias and lymphomas in adults; acute leukemia of childhood.

Edematous States: To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.

Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis.

Nervous System: acute exacerbations of multiple sclerosis; management of edema associated with brain tumour.

Miscellaneous: Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.

Organ Transplantation.

Predmet Tablets - Dosage

The initial recommended dosage of Predmet Tablets (methylprednisolone) may vary from 4 to 48 mg per day depending on the specific indication being treated.

Predmet Tablets - Contraindications

Predmet (methylprednisolone) Tablets are contraindicated in patients that have Systemic fungal infections. It is also contraindicated in persons that have a known hypersensitivity to methylprednisolone or any other component of the tablets.

Side Effects Of Predmet Tablets ( Methylprednisolone)

The side effects of Methylprednisolone tablets are given below:

Fluid and Electrolyte Disturbances:

• Sodium retention


• Congestive heart failure in susceptible patients


• Hypertension


• Fluid retention


• Potassium loss


• Hypokalemic alkalosis

Musculoskeletal:

• Muscle weakness


• Loss of muscle mass


• Steroid myopathy


• Osteoporosis


• Tendon rupture, particularly of the Achilles tendon


• Vertebral compression fractures


• Aseptic necrosis of femoral and humeral heads


• Pathologic fracture of long bones

Gastrointestinal:

• Peptic ulcer with possible perforation and hemorrhage


• Pancreatitis


• Abdominal distention


• Ulcerative esophagitis


• Increases in alanine transaminase (ALT, SGPT), aspartate transaminase (AST, SGOT), and alkaline phosphatase

Dermatologic :

• Impaired wound healing


• Petechiae and ecchymoses


• May suppress reactions to skin tests


• Thin fragile skin


• Facial erythema


• Increased sweating

Neurological:

• Increased intracranial pressure with papilledema (pseudo-tumor cerebri) usually after treatment


• Convulsions


• Vertigo


• Headache

Endocrine:

• Development of Cushingoid state


• Suppression of growth in children


• Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness


• Menstrual irregularities


• Decreased carbohydrate tolerance


• Manifestations of latent diabetes mellitus


• Increased requirements of insulin or oral hypoglycemic agents in diabetics

Ophthalmic:

• Posterior subcapsular cataracts


• Increased intraocular pressure


• Glaucoma


• Exophthalmos

Metabolic:

• Negative nitrogen balance due to protein catabolism

Further Information

Prescribing Information

Lametec Tablets | Generic Lamictal | Lamotrigine | Dosage | Uses | Side effects

Lametec Tablets (Generic Lamictal) - Active Ingredient And Chemical structure

The active ingredient contained in Lametec Tablets is Lamotrigine. Lamotrigine is a white to pale cream-colored powder and is very slightly soluble in water (0.17 mg/mL at 25°C) and slightly soluble in 0.1 M HCl. The structure is shown below

Generic Forms and Brand names of Lamictal

Lametec Tablets manufactured by Cipla Ltd., India is an effective treatment for Epilepsy adjunctive and mono therapy, generalized seizures of Lennox-Gastaut syndrome and Bipolar Disorder. Generic Lamictal which has the active ingredient Lamotrigine is also sold under various other brand names.

Lamictal Tablets (Lamotrigine) - Uses

Lamotrigine, an antiepileptic drug (AED) in the form of Lametec Tablets is used to treat the following indications:
Epilepsy-adjunctive therapy in patients 2 years of age or more:
partial seizures.
primary generalized tonic-clonic seizures.
generalized seizures of Lennox-Gastaut syndrome.

Epilepsy—monotherapy in patients 16 years of age or greater:
conversion to monotherapy in patients with partial seizures who are receiving treatment with carbamazepine, phenobarbital, phenytoin, primidone, or valproate as the single AED.

Bipolar Disorder in patients 18 years of age and above:
maintenance treatment of Bipolar I Disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy.

Lametec Tablets (Generic Lamictal) - Preparations

Lametec is available as tablets of 25 mg, 50 mg and 100 mg .Each dispersible tablet contains Lamotrigine 25 mg, 50 mg and 100 mg respectively.

Lametec Tablets - Storage Requirements

Lametec Tablets are to be stored at room temperature (15°C to 30°C). Store away from heat, moisture, and light.

Lametec Tablets (Lamotrigine) - Mechanism of Action

The exact ways by which lamotrigine (Lametec Tablets) exerts its anticonvulsant action are unknown. In animal models that were designed to detect anticonvulsant activity, lamotrigine was effective in preventing seizure spread in the maximum electroshock (MES) and pentylenetetrazol (scMet) tests, and prevented seizures in the visually and electrically evoked after-discharge (EEAD) tests for antiepileptic activity.

Lametec Tablets (Lamotrigine) - Dosage

The Dosage for Lametec Tablets is based on concomitant medications, indication, and the age of the patient. To avoid an increased risk of rash, the recommended initial dose and subsequent dose escalations should not be exceeded. Lametec (Lamotrigine) Tablets should be swallowed with water.

Monotherapy with Lametec in patients 16 years of age or more:

Lametec is to be titrated to the targeted dose of 50 mg/day while maintaining the dose of the enzyme-inducing antiepileptic drugs(EIAEDs) at a fixed level. The EIAEDs are then gradually withdrawn over a period of 4 weeks.Recommended maintenance dose of Lametec DT as monotherapy is 500 mg/day given in two divided doses.
Bipolar Disorder:
The recommended initial adult dosage of Lametec DT is 25 mg once daily for 2 weeks, followed by 50 mg once daily for 2 weeks.
The recommended adult (over 12 years) dosage for lametec (mg/day) is given below

	Weeks 1 & 2	Weeks 3 & 4	Usual Maintenance Dose
With enzyme-inducing antiepileptic drugs(EIAEDs) & No Valproic acid (VPA)	50mg/day (Once a day)	100mg/day (Two divided doses)	300mg to 500mg/day (Two divided doses). To achieve maintenence doses may be incresed by 100mg/day every 1-2 weeks
EIAEDs & Valproic acid (VPA)	25 mg every other day	25mg (Once a day)	100mg to 400mg/day (Two divided doses). To achieve maintenence doses may be incresed by 25 mg - 50mg/day every 1-2 weeks

As there exists a risk of rash the initial dose and subsequent dose escalation should not be exceeded.

The recommended dose escalation for lamotrigine (lametec) for children aged 2-12 years (total daily dose in mg/kg body weight/day) on combined drug therapy is given below.

	Weeks 1 & 2	Weeks 3 &	Usual Maintenance Dose
With AED regimen containing VPA	0.15mg/kg/day (1 or 2 divided doses)	0.3mg/kg/day (1 or 2 divided doses)	1mg - 5mg/kg/day (Maximum 200mg/day in One or Two divided doses)To achieve maintenence doses may be incresed by 0.5 - 1mg/kg/day every 1-2 weeks
Added to EIAEDs and wirhout VPA	0.6mg/kg/day (2 divided doses)	1.2mg/kg/day (2 divided doses)	5mg - 15mg/kg/day (Maximum 400mg/day in One or Two divided doses)To achieve maintenence doses may be incresed by 2 - 3mg/kg/day every 1-2 weeks

After initial 4 weeks of therapy, the daily dosage of Lametec DT may be doubled at weekly intervals until an effective maintenance dosage of 200 mg daily is reached. The daily dosages should not exceed 200 mg daily.

Lametec DT Tablets - Contraindications

Lametec DT Tablets are contraindicated in patients who have demonstrated hypersensitivity to Lamotrigine or any inactive ingredient present in the medicine.

Side Effects Of Lametec DT Tablets (Generic Lamictal or Lamotrigine)

The common adverse effects (incidence 10% or greater) of Lamotrigine (Lametec DT Tablets) in adult epilepsy clinical studies were dizziness, headache, diplopia, ataxia, nausea, blurred vision, somnolence, rhinitis, and rash.
Additional adverse reactions (incidence 10% or greater) reported in children in epilepsy clinical studies included vomiting, infection, fever, accidental injury, pharyngitis, abdominal pain, and tremor. Most common adverse effects with an incidence rate 5% or more in adult bipolar clinical studies were nausea, insomnia, somnolence, back pain, fatigue, rash, rhinitis, abdominal pain, and xerostomia.

Further Information

Prescribing Information